methyl 1-aminoindane-5-carboxylate | 1097196-76-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: methyl 1-aminoindane-5-carboxylate
• 英文别名: methyl 1-amino-2,3-dihydro-1H-indene-5-carboxylate
• CAS: 1097196-76-3
• 化学式: C₁₁H₁₃NO₂
• mdl: MFCD18650502
• 分子量: 191.23
• InChiKey: UOFGALYVZHUWOQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  甲醇 、 1-aminoindane-5-carbonitrile hydrochloride 在 硫酸 、 potassium carbonate 作用下， 以 水 、 甲醇 为溶剂， 反应 72.0h， 生成 methyl 1-aminoindane-5-carboxylate
  参考文献：
  名称：

  EP2172447

  摘要：

  公开号：

文献信息

• Heterobicyclic metalloprotease inhibitors
  申请人：Gallagher M. Brian

  公开号：US20070155737A1

  公开（公告）日：2007-07-05

  The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic ADAMTS-4 inhibiting compounds.

  本发明通常涉及含有酰胺基团的药物，特别是含有酰胺基团的杂双环金属蛋白酶抑制剂化合物。更具体地，本发明提供了一类新的杂双环ADAMTS-4抑制剂化合物。
• AMIDE COMPOUNDS
  申请人：Nozawa Eisuke

  公开号：US20110028463A1

  公开（公告）日：2011-02-03

  [Problems] To provide a compound that is useful as an agent for treating chronic renal insufficiency or an agent for treating diabetic nephropathy. [Means for Solving Problems] The present inventors have conducted extensive studies on a compound having an EP4 receptor antagonistic action, and as a result, they have found that various amide derivatives having a carboxylic group or an equivalent thereof exhibit an excellent EP4 receptor antagonistic action, thereby completing the present invention. Since the compound of the present invention has an excellent EP4 receptor antagonistic action, it is useful as an agent for preventing and/or treating chronic renal insufficiency or diabetic nephropathy.

  【问题】提供一种可用作治疗慢性肾功能不全或糖尿病肾病的药物化合物。 【解决问题的方法】本发明者对具有EP4受体拮抗作用的化合物进行了广泛的研究，结果发现具有羧酸基或其等效物的各种酰胺衍生物表现出优异的EP4受体拮抗作用，从而完成了本发明。由于本发明的化合物具有优异的EP4受体拮抗作用，因此可用作预防和/或治疗慢性肾功能不全或糖尿病肾病的药物。
• AMIDE COMPOUND
  申请人：Astellas Pharma Inc.

  公开号：EP2172447A1

  公开（公告）日：2010-04-07

  [Problems] To provide a compound that is useful as an agent for treating chronic renal insufficiency or an agent for treating diabetic nephropathy. [Means for Solving Problems] The present inventors have conducted extensive studies on a compound having an EP4 receptor antagonistic action, and as a result, they have found that various amide derivatives having a carboxylic group or an equivalent thereof exhibit an excellent EP4 receptor antagonistic action, thereby completing the present invention. Since the compound of the present invention has an excellent EP4 receptor antagonistic action, it is useful as an agent for preventing and/or treating chronic renal insufficiency or diabetic nephropathy.

  [问题]提供一种可作为治疗慢性肾功能不全的药物或治疗糖尿病肾病的药物的化合物。 [解决问题的方法]本发明人对具有 EP4 受体拮抗作用的化合物进行了广泛的研究，结果发现具有羧基或其等价物的各种酰胺衍生物具有优异的 EP4 受体拮抗作用，从而完成了本发明。 由于本发明的化合物具有优异的 EP4 受体拮抗作用，因此可用作预防和/或治疗慢性肾功能不全或糖尿病肾病的药物。
• Amide compounds and their use as PGE2 antagonists.
  申请人：Astellas Pharma Inc.

  公开号：EP2460787A1

  公开（公告）日：2012-06-06

  [Problems] To provide a compound that is useful as an agent for treating chronic renal insufficiency or an agent for treating diabetic nephropathy. [Means for Solving Problems] The present inventors have conducted extensive studies on a compound having an EP4 receptor antagonistic action, and as a result, they have found that various amide derivatives having a carboxylic group or an equivalent thereof exhibit an excellent EP4 receptor antagonistic action, thereby completing the present invention. Since the compound of the present invention has an excellent EP4 receptor antagonistic action, it is useful as an agent for preventing and/or treating chronic renal insufficiency or diabetic nephropathy.

  [问题]提供一种可作为治疗慢性肾功能不全的药物或治疗糖尿病肾病的药物的化合物。 [解决问题的方法]本发明人对具有 EP4 受体拮抗作用的化合物进行了广泛的研究，结果发现具有羧基或其等价物的各种酰胺衍生物具有优异的 EP4 受体拮抗作用，从而完成了本发明。 由于本发明的化合物具有优异的 EP4 受体拮抗作用，因此可用作预防和/或治疗慢性肾功能不全或糖尿病肾病的药物。
• EP2172447
  申请人：——

  公开号：——

  公开（公告）日：——